Antiangiogenic radioimmunotherapy of human solid tumors in scid mice using125I-labeled anti-endoglin monoclonal antibodies

International Journal of Cancer

Volumn 82, Issue 5, 1999, Pages 737-742

  Tabata, Masahiro ^a   Kondo, Masao ^a   Haruta, Yuro ^a   Seon, Ben K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CROSS REACTING ANTIBODY; ENDOGLIN; IMMUNOGLOBULIN G; IODINE 125; MONOCLONAL ANTIBODY; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE ANTIGEN; RADIOACTIVE IODINE; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; SOLID TUMOR; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; ENDOTHELIUM; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); RADIATION EXPOSURE; VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, SURFACE; CELLS, CULTURED; ENDOTHELIUM; FEMALE; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RADIOIMMUNOTHERAPY; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0033609719     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19990827)82:5<737::aid-ijc18>3.3.co;2-%23     Document Type: Article

References (26)

1. AUERBACH, W. and AUERBACH, R., Angiogenesis inhibition: a review. Pharmacol. Ther., 63, 265-311 (1994).
2. 131I-labeled CO17-1A in a human colorectal cancer model. Int. J. Cancer, 76, 738-748 (1998).
3. BICKNELL, R. and HARRIS, A.L., Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin. Cancer Biol., 3, 399-407 (1992).
4. BIEDERMANN, K.A., SUN, J., GIACCIA, A.J., TOSTO, L.M. and BROWN, J.M., Seid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc. not. Acad. Sci. (Wash.), 88, 1394-1397 (1991).
5. BOEHM, T., FOLKMAN, J., BROWDER, T. and O'REILLY, M.S., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390, 404-407 (1997).
6. BÜHRING, H.-J., MÜLLER, C.A., LETARTE, M., GOUGOS, A., SAALMÜLLER, A., VAN AGTHOVEN, A.J. and BUSCH, F. W., Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia, 5, 841-847 (1991).
7. BURROWS, F.J., DERBYSHIRE, E.J., TAZZARI, P.L., AMLOT, P., GAZDAR, A.F., KING, S.W., LETARTE, M., VITETTA, E.S. and THORPE, P.E., Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin. Cancer Res., 1, 1623-1634 (1995).
8. CHEIFETZ, S., BELLÓN, T., CALÉS, C., VERA, S., BERNABEU, C., MASSAGUÉ, J. and LETARTE, M., Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. biol. Chem., 267, 19027-19030 (1992).
9. CORCORAN, M.C., PRESS, O.W., MATTHEWS, D.C., APPELBAUM, F.R. and BERNSTEIN, I.D., The role of radioimmunotherapy in bone marrow transplantation. Current Opin. Haematol., 3, 438-445 (1996).
10. DENEKAMP, J., Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Brit. J. Radial., 66, 181-196 (1993).
11. DVORAK, H.F., NAGY, J.A. and DVORAK, A.M., Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells, 3, 77-85 (1991).
12. ENGERMAN, R.L., PFAFFENBACH, D. and DAVIS, M.D., Cell turnover of capillaries. Lab. Invest., 17, 738-743 (1967).
13. FOLKMAN, J., Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg., 175, 409-416 (1972).
14. FOLKMAN, J. and SHING, Y., Angiogenesis. J. biol. Chem., 267, 10931-10934 (1992).
15. GOUGOS, A. and LETARTE, M., Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol., 141, 1925-1933 (1988).
16. GRIFFIOEN, A.W., DAMEN, C.A., BLIJHAM, G.H. and GROENEWEGEN, G., Endoglin/CD 105 may not be an optimal tumor endothelial treatment target (letter to the editor). Breast Cancer Res. Treat., 39, 239-240 (1996).
17. HARUTA, Y. and SEON, B.K., Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc. nat. Acad. Sci. (Wash.), 83, 7898-7902 (1986).
18. JAIN, R.K., Barriers to drug delivery in solid tumors. Sci. Amer., 271, 58-65 (1994).
19. KAWATA, A., YOSHIDA, M., OKAZAKI, M., YOKOTA, S., BARCOS, M. and SEON, B.K., Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotion of human leukemia cells on the expression of GP160, a novel human leukemia-associated cell surface glycoprotein. Fed. Proc., 46, 1056 (1987).
20. MEREDITH, R.F., KHAZAELI, M.B., PLOTT, W.E., SPENCER, S.A., WHEELER, R.H., BRADY, L.W., WOO, D.V. and LOBUGLIO, A.F., Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J. nucl. Med., 36, 2229-2233 (1995).
21. MEREDITH, R. F., LOBUGLIO, A. F. and SPENCER, E. B., Recent progress in radioimmunotherapy for cancer. Oncology, 11, 979-988 (1997).
22. O'CONNELL K.A. and EDIDIN, M., A mouse lymphoid endothelial cell line immortalized by simian virus 40 binds lymphocytes and retains functional characteristics of normal endothelial cells. J. Immunol., 144, 521-525 (1990).
23. O'HARE, M.J., Breast cancer. In: J.R.W. Masters (ed.), Human cancer in primary culture, a handbook, pp. 271-286, Kluwer, Dordrecht (1991).
24. RISAU, W., Differentiation of endothelium. FASEB J., 9, 926-933 (1995).
25. ROKHLIN, O.W., COHEN, M.B., KUBAGAWA, H., LETARTE, M. and COOPER, M.D., Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. J. Immunol., 154, 4456-4465 (1995).
26. SEON, B.K., Specific killing of human T leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res., 44, 259-264 (1984).